About Anixa Biosciences, Inc. - Common Stock (ANIX)
Anixa Biosciences Inc is a biotechnology company focused on developing innovative solutions for the treatment of various cancers and infectious diseases. The company is engaged in the research and development of novel therapies, particularly in the areas of immuno-oncology and vaccine technology. By leveraging its proprietary platforms and collaborative partnerships, Anixa aims to advance its product pipeline and deliver transformative healthcare solutions to patients in need. The company's commitment to scientific excellence and patient outcomes drives its mission to address unmet medical needs and improve the quality of life for those affected by serious health challenges. Read More
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.
Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.
FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising results.
Anixa Biosciences (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. For more information, visit the company’s website at www.anixa.com .
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
2023 witnessed a remarkable flurry of activity in the biopharmaceutical industry, with several high-profile acquisitions underscoring the sector's dynamic nature and its relentless pursuit of innovation. Here’s a look at some of the most significant deals that not only made headlines but are set to reshape the therapeutic landscape.
NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 17-18, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Anixa Biosciences (NASDAQ: ANIX) is an interesting, undiscovered biotech company that seeks to disrupt the cancer landscape by working with some highly credible partners. The company is undiscovered for many reasons including its history.
SAN JOSE, CA / ACCESSWIRE / August 10, 2023 / Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the human immune system has led to the development of innovative immuno-therapy drugs that have been approved and commercialized.
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the human immune system has led to the development of innovative immuno-therapy drugs that have been approved and commercialized.
